Evaluation of the effects of thymol vaginal cream on bacterial vulvovaginitis

Phase 2

Recruiting

• Conditions: Bacterial vulvovaginitis (Trichomonas vaginalis).; Trichomonal vulvovaginitis; A59.01

• Registration Number: IRCT20191106045356N12
• Lead Sponsor: Yazd University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Female
Married
Patients with bacterial vulvovaginitis based on ASMEL criteria
Willingness to participate in the study and complete the ethical consent form

Exclusion Criteria

Irritation or allergic reaction to the drug
Aggravation of symptoms caused by infection
Not taking medicine for more than one day
Women who are pregnant, breastfeeding, have immune deficiency or malignancy
History of mental disorders and psychosis
Allergic reactions following consumption of thymol or products containing thymol

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complaints and clinical observations. Timepoint: Evaluation of complaints and clinical observations on days 1, 3 and 7 days after starting the use of thymol vaginal cream. Method of measurement: Likert scale.

Secondary Outcome Measures

Name	Time	Method
Clinical observations and complaints. Timepoint: At the beginning of the study and after days 1, 3 and 7 days after starting to use the vaginal cream. Method of measurement: Likert scale.